HUNTINGTON BEACH, California and AMSTERDAM, December 13 /PRNewswire/ --
- Recent Study Reveals Substantial Group of Traditionally Miscategorized HER2+ Patients
Dr. Michael Knauer from the Netherlands Cancer Institute today announced data uncovering a substantial group of traditionally miscategorized low risk HER2+ patients. Agendia's highly accurate breast cancer tumor recurrence test, MammaPrint(R), was used to differentiate between patients at high and low risk for recurrence.